© 2020-23 BizApprise. All rights reserved.

Dr. Reddy’s Laboratories: Owner, NSE Share Price [2023]

Profile of Dr. Reddy’s Laboratories, Products List and share price, List of DrReddy’s subsidiaries along with the owner, awards, and financial data. Dr. Reddy’s core value is to make affordable medicines while maintaining the high-quality for users all around the world, with an overall focus to develop the pharma industry of India.

The company initially focused on the production of APIs but later expanded into finished dosage forms and biotechnology products. Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high-quality, affordable, and innovative medicines across therapy areas.

The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and the New York Stock Exchange in the United States.

Dr. Reddy’s Laboratories Ltd: Overview

Dr. Reddy’s Laboratories is one of the best pharma companies in India based in Hyderabad, Telangana, India. Dr. Reddy’s Laboratories was founded in 1984 by Anji Reddy, a former scientist at the Indian Council of Scientific and Industrial Research (CSIR). The company manufactures and markets a wide range of pharmaceuticals in India and abroad.

Its products include active pharmaceutical ingredients (APIs), finished dosage forms, and biotechnology products. The company has a strong presence in the generic drug market in the United States, and its products are also sold in over 150 other countries.

The company has grown rapidly, and today it is one of the leading pharmaceutical companies in India. Dr. Reddy’s Laboratories is a research-based company, and its products are developed through a rigorous R&D process.

The company has a dedicated R&D center in Hyderabad, which is one of the largest in the country. The company’s R&D efforts have led to the development of several innovative products, such as the world’s first biosimilar insulin.

Dr. Reddy’s Laboratories is committed to providing affordable and accessible medicines to patients around the world. The company has a strong social responsibility program, and it is actively involved in initiatives to improve access to healthcare in rural areas of India.

The company’s mission is to “provide affordable and innovative medicines for a healthier world.” The company is dedicated to improving the lives of patients and making a positive impact on society.

Dr. Reddy Share Price

Dr. Reddy's Laboratories Ltd - SHARE PRICE NSE DRREDDY
Source: TradingView

Here is Dr. Reddy’s Laboratories’ Share price from NSE. The LTP as on 26 April 2023 is Rs. 4,847.45. Follow the below Cipla share Price chart on a Monthly time frame.

Dr. Reddy contributes a third massive weightage after Sun Pharma and Cipla of a whopping 12.09% in the Nifty Pharma Index.

Dr. Reddy’s Labs Fundamentals

Dr. Reddy's Laboratories Ltd - Fundamentals
Source: Finology

Key Fundamentals of Dr. Reddy’s Laboratories:

  • MARKET CAP: ₹ 73,467.34 Cr.
  • COMPANY VALUE: ₹ 73,642.24 Cr.
  • Nifty Pharma Weightage: 12.09
  • P/E: 30.91
  • DIVIDEND YIELD: 0.68 %
  • PROMOTER HOLDING: 26.71 %
  • SALES GROWTH: 7.91%
  • ROE: 9.26 %
  • ROCE: 11.68%

Where does it stand among other top pharma companies?

DrReddy Holds 4th position among best phama companies in India in terms of Market Cap
Source: Finology

Dr. Reddy’s Laboratories: Products List

Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations.

Products Categories

  • Generics
  • Over-the-counter
  • APIs (Active Pharmaceutical Ingredients)
  • Biologics
  • Differentiated Formulations

Here are the top brands from Dr. Reddy’s Labs:

1. Nise: Nise tablet (Nimesulide 100 mg) belongs to a group of drugs called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).

2. Clamp: Clamp 625 tablet is a combination of Amoxycillin (500 mg) and Potassium Clavulanate (125 mg). It belongs to the anti-infective class of drugs.

3. Omez: Omez capsule (Omeprazole 20 mg) belongs to a group of drugs called Proton Pump Inhibitors (PPIs).

4. Stamlo: Stamlo 2.5/5/10 tablets (Amlodipine 2.5/5/10mg) belong to a group of drugs called calcium channel blockers.

5. Razo: Razo 10/20 tablets (Rabeprazole sodium 10/20) belong to a group of drugs called Proton Pump Inhibitors (PPIs).

6. Econorm: Econorm is a probiotic that contains live cells of Saccharomyces boulardii (250 mg).

7. Senquel – F: Senquel F is a desensitizing toothpaste and contains a potassium nitrate formulation.

8. Ketoral: Ketorol DT (Ketorolac Tromethamine 10 mg) is a dispersible tablet that belongs to a group of drugs called analgesics.

9. Atocor: Atocor 5/10/20/40/80 mg tablets (Atorvastatin) belong to a group of drugs called statins.

10. Mintop: Mintop-10 (topical Minoxidil 100 mg) is used to treat male-pattern baldness.

11. Venusia: Venusia cream (aloe vera, squalene, vitamin E) is a moisturizer from Dr. Reddy’s Laboratories.

12. Glimy: Glimy 1/2/3/4 (Glimepiride 1/2/3/4 mg) tablets belong to a group of drugs called sulfonylureas (SUs).

13. Telsartan Activ: Telsartan 20/40/80 (Telmisartan 20/40/80 mg) tablets belong to a group of drugs called angiotensin receptor blockers.

Dr. Reddy’s Awards

  • India’s Best Managed Boards by Mint and Aon Hewitt and by Economic Times and Hays in their respective studies.
  • India’s Best Companies to Work For in the Biotechnology and Pharmaceuticals Sector by Great Place To Work Institute.
  • Global Generics & Biosimilar Award 2018 for CSR initiative of the year.
  • India Pharma Corporate Social Responsibility (CSR) Programme of the Year Award 2018 by the Department of Pharmaceuticals, Government of India.
  • Dr. Reddy’s ranked among the top 10 in the Forbes China 2018 list of leading Indian Companies in China.
  • Dr. Reddy’s inclusion in the 2019 Bloomberg Gender-Equality Index.
  • Global Generics & Biosimilars Award 2019: API supplier of the Year at the 6th Annual Global Generics & Biosimilars Awards.
  • Winner of the Golden Peacock International Award for Sustainability for the year 2019.

End Words on Dr. Reddy’s Laboratories Ltd.

In conclusion, Dr. Reddy’s Laboratories is a leading pharmaceutical company that is dedicated to providing quality medicines to patients around the world. The company has a strong research and development program and a commitment to improving the lives of patients. Dr. Reddy’s Laboratories is a trusted partner in the healthcare industry and a company that is committed to making a difference.

Aayush
Aayush

Aayush has 7+ years of experience in content writing and leads cybersecurity and the latest technologies including Web 3.0 for TechApprise, an educational hub for online security, startups, apps, and more. With a background in digital marketing, Aayush also helps brands create digital experiences and build their businesses through organic search.

Articles: 47

Leave a Reply

Your email address will not be published. Required fields are marked *